Baird Maintains Neutral on Intellia Therapeutics, Raises Price Target to $85
Baird analyst Madhu Kumar maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $60 to $85.
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
Intellia Therapeutics On Jun. 14 Entered Amendment To Collaborative Research Agreement With Novartis; Amendment Amends Novartis’ Rights With Respect To CAR-T Therapeutic Targets Under Agreement
On June 14, 2021, Intellia Therapeutics, Inc. (“Intellia”) entered into Amendment #3 (the “Amendment”) to its License and Collaborative Research Agreement (the “Collaboration
Intellia Therapeutics Highlights Will Present Interim Clinical Data From Ongoing Phase 1 Study Of NTLA-2001 For Treatment Of Transthyretin Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting Jun. 26
Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate
Late-breaking abstract selected for oral presentation on June
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell
• ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.